Allergen Immunotherapy with Depigmented-Polymerised Cat Allergoid Is Safe and Well-Tolerated in Patients with Allergic Rhinitis/Rhinoconjunctivitis.

ABSTRACT: Background/Objectives: For decades, only native allergen extracts with a high incidence of adverse drug reactions (ADRs) were available for allergen-specific immunotherapy (AIT)-generally administered subcutaneously-to treat allergy to feline epithelia. Modified allergen extracts are a promising alternative to reduce the number of ADRs. The purpose of this study was to collect data on the safety of a depigmented-polymerised cat allergoid under real-world conditions in clinical routine. Methods: This study was designed as a voluntary non-interventional post-authorisation safety study (NIS-PASS), specifically focusing on adverse events (AEs)-including ADRs-that occur upon injection and assessing the influence on quality of life (QoL). The observation period was the initial phas

SUBMITTER: Mosges R 

PROVIDER: S-EPMC12692814 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature